Why the study?
Does loading daunorubicin into Fe(3)O(4) magnetic nanoparticles improve its safety and biocompatibility profile in preclinical models?
Population
Mice and in vitro models to explore potential application in hematologic malignancies
Comparison
Self-assembled FeO magnetic nanoparticles loaded… vs Negative controls, positive controls, and…
Design
Preclinical
Follow-up
Up to 72 hours for acute toxicity
Authors
Loading...
May support further preclinical testing in hematologic models; leaves open human safety and efficacy translation.
Does loading daunorubicin into Fe(3)O(4) magnetic nanoparticles improve its safety and biocompatibility profile in preclinical models?
Fe(3)O(4)-MNPs/DNR demonstrate high biocompatibility and a significantly higher LD50 than daunorubicin alone in preclinical models, suggesting a wide safety margin for potential use in hematologic malignancies.
Wu et al. (2010) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: